viewCellmid Limited

Cellmid becomes profitable in December after achieving record quarterly sales

The company continued its sales growth trajectory while substantially reducing its debt.

The company is well-funded with $5.4 million cash on hand

Cellmid Limited (ASX:CDY) has posted record sales for the second quarter of financial year 2019, earning $2.2 million or an 8% increase on the same period last year.

The company became profitable for the month of December 2018 with $278,000 net profit after tax received.

Sales growth continued across all of Cellmid’s divisions, with the USA recording the highest growth rate while Japan remains the largest contributor in terms of sales revenue.

Cellmid continued preparation of its orphan drug application during the quarter and expects to complete a filing during the March quarter.


Cellmid chief executive officer Maria Halasz said: “Our cash position will be further boosted in quarter three financial year 2019 as our record accounts receivable arrives.

“In addition, we have repaid all of our major debt and we are now in a strong financial position to fulfil growth expectations in current and new channels.”

READ: Cellmid driving towards profitability with anti-ageing product range

The company’s cash balance at the end of the December quarter was $5.4 million, down from $9.26 million at the end of the previous quarter.

The current receivables balance is over $1.5 million which Cellmid expects to contribute to strong cash receipts in the coming March quarter.

Significant cash outflows during the quarter included the repayments of the remaining Platinum Road loan facility with interest.

READ: Cellmid expecting record sales in December quarter, shares up 15%

Part of the company’s growth strategy has been securing the supply chain for évolis activator bottles and other packaging products.

During the quarter, Cellmid placed major orders for supplies of évolis product components to rapidly fulfil orders in the growing US and Japanese distribution.

évolis is a clinically-validated portfolio of anti-ageing hair treatments


READ: Cellmid partners with NZ pharmacies to distribute anti-ageing products

In November last year the company’s Lyramid patent application, entitled ‘Antibody recognizing N-domain of midkine’, was granted by the US Patent Office.

Cellmid has also received a notification of intention to grant from the European Patent Office for the corresponding Lyramid patent in key European territories.

The newly-granted midkine antibody patents and allied patent families underpin Cellmid’s intellectual property position over the use of therapeutic midkine antibodies.

This includes their use in treating diseases such as cancer, chronic inflammation, surgical adhesions and functional disorders in T-regulatory cells associated with autoimmune disease.

READ: Cellmid builds IP for midkine portfolio with new patents

Cellmid is an Australian life sciences company with lead programs in multiple disease indications.

The company develops and markets novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss.

Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine and FGF5 globally.

Quick facts: Cellmid Limited

Price: 0.185 AUD

Market: ASX
Market Cap: $22.33 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...



Cellmid is a well funded life sciences company that see a path to profitability

Cellmid (ASX:CDY) Chief Executive and Managing Director Maria Halasz sat down with Christine Corrado from Proactive Investors New York to discuss their biotech company that now has products available in the United States. Halasz telling Proactive they are about to spin out into 2...

on 05/15/2019

3 min read